|
| Primary information |
|---|
| ID | 10681 |
| Therapeutic ID | Th1149 |
| Protein Name | Ragweed Pollen Extract |
| Sequence | NA
|
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | NA |
| Description | Ragweed pollen extract has been developed by Curalogic. The company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy. While traditional disease-modifying immunotherapeutics are administered by subcutaneous injection, Curalogic has developed a more convenient orally administered drug. |
| Indication/Disease | Investigated for use/treatment in allergic reaction. |
| Pharmacodynamics | Precise mechanism of allergen immunotherapy is not known |
| Mechanism of Action | Ragweed pollen extract is the oral immunotherapy delivered via microencapsulated beads put into a capsule, which enables the antigen to be delivered more efficiently to the Peyer's patches in the jejunum and duodenum, where the antigen can be presented and processed and not destroyed by stomach acid. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| NA |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Brand Name | Ragwitek |
| Company | Merck Sharp & Dohme |
| Brand Description | Merck Sharp & Dohme |
| Prescribed For | Ragwitek is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis, with or withoutconjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. Ragwitek is approved for use in adults 18 through 65 years of age. |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | Tablets |
| Route of Administration | Oral route |
| Recommended Dosage | One ragwitek tablet daily. |
| Contraindication | Ragwitek is contraindicated in patients with severe, unstable or uncontrolled asthma, history of any severe systemic allergic reaction, history of any severe local reaction after taking any sublingual allergen immunotherapy, history of eosinophilic esophagitis and hypersensitivity to any of the inactive ingredients [gelatin, mannitol, and sodium hydroxide] contained in this product. |
| Side Effects | Throat irritation, oralpruritus, ear pruritus, oral paraesthesia, mouth edema, and tongue pruritus. |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |